A profoundly positive response from Anglonordic attendees with hands shaken, conversations started and potential deals in the works. The main takeaway was the benefit of it being a ‘boutique’ event, meaning everyone could make the most of the 1:1 partnering, pitch presentations, and networking breaks. Keep reading to hear more about what’s been happening this […]
Drum roll… In Vivo’s 2026 Rising Leaders were announced this week and included not one, not two, but five Optimum clients. A huge congratulations to Colleen Acosta of Freya Biosciences, Diana Čekatauskaitė of Lonza’s Synaffix, Reuben Dawkins of Link Biologics, Michelle Morrow of Nucleome Therapeutics, and Javier Nunez-Vicandi of Sofinnova Partners. This list recognises not […]
Easter may be over, but momentum across life sciences is building. Anglonordic Life Science Conference is less than two weeks away, alongside a steady stream of clinical progress, partnerships, and industry milestones, it’s all go! Our latest Optimum TV episode features Stephen Hansen of BioCentury and offers fresh insights into market trends and the Q2 […]
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease R1 Therapeutics, Inc, a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with kidney disease, announced its launch with an oversubscribed $77.5 million Series A financing, along with the […]
Novo Nordisk Foundation announced it had awarded DKK 11.8 billion (€1.6 billion) during 2025 to support more than 2,200 projects aimed at improving people’s health and the sustainability of society and the planet. The projects cover the full range of the Foundation’s grant-giving areas, including key topics such as cardiometabolic diseases, antimicrobial resistance, the development of more resilient and climate-friendly […]
